[Thromboembolic events at the time of highly active antiretroviral therapies against human immunodeficiency virus]

Rev Med Interne. 2008 Feb;29(2):100-4. doi: 10.1016/j.revmed.2007.10.417. Epub 2007 Nov 26.
[Article in French]

Abstract

Purpose: Vein thrombosis risk and pulmonary embolism seem to be more important among human immunodeficiency virus (HIV) infected patients.

Method: We performed a retrospective study including 780 HIV positive patients followed-up between January 2000 and June 2005 at the University Hospital of Clermont-Ferrand.

Results: Among the 780 HIV-infected patients, six cases of thromboembolic events were identified including, four with pulmonary embolism. All the patients were receiving lopinavir/ritonavir combination.

Conclusion: Although uncommon, pulmonary embolism occurs more frequently among HIV positive patients than in general population. Clinicians must remain aware about the possibility of the occurrence of a thromboembolic event especially during the first few months after introduction of the antiretroviral therapy.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active / statistics & numerical data*
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • France / epidemiology
  • HIV Protease Inhibitors / therapeutic use
  • HIV Seropositivity / epidemiology
  • Humans
  • Lopinavir
  • Male
  • Middle Aged
  • Pulmonary Embolism / epidemiology*
  • Pyrimidinones / therapeutic use
  • Retrospective Studies
  • Ritonavir / therapeutic use
  • Venous Thrombosis / epidemiology*

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • Pyrimidinones
  • Lopinavir
  • Ritonavir